Thyroid dysfunction after atezolizumab and bevacizumab is associated with favorable outcomes in hepatocellular carcinoma (IMbrave150 and Korean patients cohorts)

被引：0
|
作者：
Chon, H. [1 ]
Song, Y. S. [2 ]
Yang, H. [3 ]
Kim, I. [4 ]
Hye-Young, K. [5 ]
Lee, W. S. [6 ]
Sang, Y. B. [7 ]
Kim, C. [8 ]
机构：
[1] Bundang Cha Med Ctr, Med Oncol, Seongnam, South Korea
[2] CHA Bundang Med Ctr, Div Endocrinol & Metabolsim, Seongnam, South Korea
[3] Bundang Cha Med Ctr, Oncol, Seongnam, South Korea
[4] Inje Univ, Med Oncol, Haeundae Paik Hosp, Busan, South Korea
[5] Ulsan Univ Hosp, Med oncol, Ulsan, South Korea
[6] Bundang Cha Med Ctr, Lab Translat Immunooncol, Seongnam, South Korea
[7] CHA Bundang Med Ctr, Hematol & Oncol, Seongnam, South Korea
[8] Bundang Cha Med Ctr, Dept Med Oncol, Seongnam, South Korea
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
基金：
新加坡国家研究基金会;
关键词：
D O I：
10.1016/j.annonc.2023.09.2137
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
993P
引用
收藏
页码：S611 / S611
页数：1
相关论文
共 50 条
  • [1] Thyroid Dysfunction After Atezolizumab and Bevacizumab is Associated with Favorable Outcomes in Hepatocellular Carcinoma
    Song, Young Shin
    Yang, Hannah
    Kang, Beodeul
    Cheon, Jaekyung
    Kim, Ilhwan
    Kim, Hyeyeong
    Lee, Won Suk
    Sang, Yun Beom
    Jung, Sanghoon
    Lim, Ho Yeong
    Gaillard, Vincent E.
    Kim, Chan
    Chon, Hong Jae
    LIVER CANCER, 2024, 13 (01) : 89 - 98
  • [2] Disease Etiology and Outcomes After Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma: Post-Hoc Analysis of IMbrave150
    Espinoza, Magdalena
    Muquith, Maishara
    Lim, Mir
    Zhu, Hao
    Singal, Amit G.
    Hsiehchen, David
    GASTROENTEROLOGY, 2023, 165 (01) : 286 - +
  • [3] Trajectories of α-fetoprotein and unresectable hepatocellular carcinoma outcomes receiving atezolizumab plus bevacizumab: a secondary analysis of IMbrave150 study
    Lu, Linbin
    Zheng, Peichan
    Pan, Yan
    Huang, Shanshan
    Shao, Erqian
    Huang, Yan
    Wang, Xuewen
    Chen, Yayin
    Cuo, Gongbao
    Yang, Hongyi
    Guo, Wangting
    Shi, Yanhong
    Wu, Zhixian
    Chen, Xiong
    BRITISH JOURNAL OF CANCER, 2023, 129 (04) : 620 - 625
  • [4] Trajectories of α-fetoprotein and unresectable hepatocellular carcinoma outcomes receiving atezolizumab plus bevacizumab: a secondary analysis of IMbrave150 study
    Linbin Lu
    Peichan Zheng
    Yan Pan
    Shanshan Huang
    Erqian Shao
    Yan Huang
    Xuewen Wang
    Yayin Chen
    Gongbao Cuo
    Hongyi Yang
    Wangting Guo
    Yanhong Shi
    Zhixian Wu
    Xiong Chen
    British Journal of Cancer, 2023, 129 : 620 - 625
  • [5] Evaluation of hyperprogressive disease with atezolizumab plus bevacizumab for hepatocellular carcinoma: A secondary analysis of the IMbrave150 trial
    Gao, Yuan
    Cheng, Ann-Lii
    Li, Lee X.
    Parent, Natalie
    Kichenadasse, Ganessan
    Karapetis, Christos S.
    Rowland, Andrew
    Hopkins, Ashley M.
    Sorich, Michael J.
    INTERNATIONAL JOURNAL OF CANCER, 2025,
  • [6] Atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma: safety results from the Phase III IMbrave150 study
    Ducreux, Michel
    Zhu, Andrew
    Qin, Shukui
    Ikeda, Masafumi
    Kim, Tae-You
    Lim, Ho Yeong
    Kudo, Masatoshi
    Breder, Valeriy
    Merle, Philippe
    Kaseb, Ahmed
    Li, Daneng
    Verret, Wendy
    Xu, Zhen
    Hernandez, Sairy
    Liu, Juan
    Shao, Hui
    Huang, Chen
    Cheng, Ann-Lii
    Finn, Richard
    Galle, Peter
    JOURNAL OF HEPATOLOGY, 2020, 73 : S121 - S121
  • [7] Characterization of response to atezolizumab plus bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial
    Salem, Riad
    Li, Daneng
    Sommer, Nicolas
    Hernandez, Sairy
    Verret, Wendy
    Ding, Beiying
    Lencioni, Riccardo
    CANCER MEDICINE, 2021, 10 (16): : 5437 - 5447
  • [8] Atezolizumab plus bevacizumab vs sorafenib for unresectable hepatocellular carcinoma: Results from older adults enrolled in IMbrave150
    Li, D.
    Toh, H.
    Merle, P.
    Tsuchiya, K.
    Hernandez, S.
    Shao, H.
    Mulla, S.
    Ding, B.
    Kudo, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S234 - S234
  • [9] Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial
    Yim, Sun Young
    Lee, Sung Hwan
    Baek, Seung-Woo
    Sohn, Bohwa
    Jeong, Yun Seong
    Kang, Sang-Hee
    Park, Kena
    Park, Hyewon
    Lee, Sunyoung S.
    Kaseb, Ahmed O.
    Park, Young Nyun
    Leem, Sun-Hee
    Curran, Michael A.
    Kim, Ji Hoon
    Lee, Ju-Seog
    CLINICAL AND MOLECULAR HEPATOLOGY, 2024, 30 (04)
  • [10] Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria
    Sho, Takuya
    Suda, Goki
    Ogawa, Koji
    Kimura, Megumi
    Kubo, Akinori
    Tokuchi, Yoshimasa
    Kitagataya, Takashi
    Maehara, Osamu
    Ohnishi, Shunsuke
    Shigesawa, Taku
    Nakamura, Akihisa
    Yamada, Ren
    Ohara, Masatsugu
    Kawagishi, Naoki
    Natsuizaka, Mitsuteru
    Nakai, Masato
    Morikawa, Kenichi
    Furuya, Ken
    Baba, Masaru
    Yamamoto, Yoshiya
    Suzuki, Kazuharu
    Izumi, Takaaki
    Meguro, Takashi
    Terashita, Katsumi
    Ito, Jun
    Miyagishima, Takuto
    Sakamoto, Naoya
    HEPATOLOGY RESEARCH, 2021, 51 (09) : 979 - 989
12345